News for Unity Biotechnology, Inc. (UBX)

On June 30, 2025, Empery Asset Management, LP (Trades, Portfolio) executed a significant transaction involving Volcon Inc (VLCN), reducing its holdings by 26,04

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Unity Biotechnology (UBX) has been downgraded by H.C. Wainwright from a "Buy" to a "Neutral" rating, with its price target reduced to $2 from $4. This adjustmen

On March 31, 2025, Empery Asset Management, LP (Trades, Portfolio) made a significant move by acquiring an additional 414,569 shares of Volcon Inc (VLCN) at a p

On March 31, 2025, Empery Asset Management, LP (Trades, Portfolio), a prominent investment firm, executed a significant transaction involving BTC Digital Ltd (B

On March 31, 2025, Empery Asset Management, LP (Trades, Portfolio) executed a significant reduction in its holdings of Flora Growth Corp (FLGC). The firm decrea

UNITY Biotechnology (UBX) has unveiled the complete 36-week findings from their Phase 2b ASPIRE trial, focusing on the intravitreal treatment UBX1325 for patien

UBX1325 demonstrated vision gains that were comparable and statistically non-inferior to aflibercept at week 36 in a difficult-to-treat DME patient population

**media[614539]**

SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (”œUNITY”) [ UBX], a biotechnology company developing therapeutics

Empery Asset Management, LP (Trades, Portfolio), a prominent investment firm, recently made a significant adjustment to its holdings in Knightscope Inc. On Marc

On March 31, 2025, Empery Asset Management, LP (Trades, Portfolio) executed a transaction involving Sobr Safe Inc (SOBR), reducing its holdings by 2,217 shares.

On March 31, 2025, Empery Asset Management, LP (Trades, Portfolio) made a significant move by reducing its holdings in Bullfrog AI Holdings Inc by 46.82%. This

Empery Asset Management, LP (Trades, Portfolio), a prominent investment firm, recently executed a significant transaction involving Sidus Space Inc. On March 31

UNITY Biotechnology, Inc. (UBX) has announced promising findings from a study published in the journal NEJM Evidence regarding its UBX1325 treatment for patient

SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (”œUNITY”) [ UBX], a biotechnology company developing therapeutic

Unity Biotechnology (UBX) reported a decrease in its cash, cash equivalents, and marketable securities, which totaled $16.9 million as of March 31. This is a de

**media[582631]**

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 350 points on Monday. The Dow traded up 1.35% to 42,551.10 while ...